Efficacy rates for China’s Covid vaccines have been found to be lower than those developed by Pfizer-BioNTech (NYSE PFE) (NASDAQ:BNTX) and Moderna. (NASDAQ MRNA) Earlier this month, the director of the Chinese Center for Disease Control publicly acknowledged that Chinese vaccines “don’t have very high protection rates” and that they were considering giving people different Covid shots to boost vaccine efficacy.
The chief medical officer of BioNTech (NASDAQ BNTX) told CNBC on Wednesday that people will likely need a third shot of its two-dose Covid-19 vaccine as immunity against the virus wanes, agreeing with previous comments made by Pfizer CEO Albert Bourla. Dr. Ozlem Tureci, co-founder and CMO of BioNTech, which developed a Covid vaccine with Pfizer (NYSE: PFE), said she also expects people will need to get vaccinated against the coronavirus annually, like for the seasonal flu.
Companies that can most efficiently decarbonize the economy will likely see strong growth for decades to come, wrote Morgan Stanley analysts in a Friday note. The group identified five industries and representative stocks that could benefit from the development.
From January 2020 through January of this year, Moderna stock has dropped significantly three times. And each time, it recovered and climbed above its previous record high. It looks like that now may be happening for the fourth time. This may be a pattern of investors locking in profits, then repurchasing shares at a lower price -- and newcomers jumping aboard too.
Bullish technical traders would like to see the stock break above the resistance line and consolidate. Consolidation above the $0.60 level could let the stock see a breakout. Bearish technical traders would like to see the stock fall below the $0.60 level. If the stock is able to break below the trendline, it could see a further downwards push.
Barron’s screened for the companies whose expected earnings have risen the most since the start of the month, meaning analysts are getting more optimistic about them heading into earnings season. The four companies below saw increases of at least 15% between April 1 and April 26.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer with potential blockbuster prospects in immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets.
As big pharma races to save millions of lives there is a smaller less known “sleeping giant” in the CAR-T space developing advanced S-layer technology with limitless applications in the key development of an intranasal vaccine.
“Biden invited 40 world leaders to the White House event, including Russian President Vladimir Putin. The invitees include 17 countries responsible for 80% of global greenhouse gas emissions, and more than 300 companies, including Apple, Walmart and Johnson & Johnson, are in favor of cutting emissions by at least 50%.